Orphan Drugs In Development For The Treatment Of Friedreich's Ataxia: Focus On Omaveloxolone.

Authors :: Ghanekar, Shaila D
Miller, Wai Wai
Meyer, Colin J
Fenelon, Kevin J
Lacdao, Alvin
Zesiewicz, Theresa A
Source :: Degenerative Neurological & Neuromuscular Disease; Oct2019, Vol. 9, p103-107, 5p
Publication Year :: 2019
Abstract: Friedreich's Ataxia (FRDA) is a devastating and progressive ataxia, marked by mitochondrial dysfunction and oxidative stress. Nrf2 activators such as omaveloxolone (Omav) modulate antioxidative mechanisms, and thus may be viable therapeutic agents in FRDA. [ABSTRACT FROM AUTHOR]

Subjects :: FRIEDREICH'S ataxia
DRUG development
ORPHAN drugs
OXIDATIVE stress
ATAXIA

Full Text Access

Tools